Tag: CSE:CBII

January 14, 2020

CB2 Insights Selected by Vireo Health to Support Medical Cannabis Clinical Trial

Partnership Underway to Develop Extensive Protocols and Submissions for US Food & Drug Administration to Uncover Safety and Efficacy for...
December 16, 2019

CB2 Insights Announces Industry’s First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.)

CB2 Insights announced that it will begin a prospective trial with GL Brands through its hemp brand and key operating...
December 12, 2019

CB2 Insights Completes Full-Scale Platform to Connect Disparate Data Systems

CB2 Insights announced its core technology platform, Sail, is now primed for streamlining and aggregating disparate healthcare data systems.
December 11, 2019

CB2 Insights Launches Warrant Incentive Program

CB2 Insights announces a warrant exercise incentive program which has been implemented to encourage the exercise of the Company’s outstanding...
December 3, 2019

CB2 Insights Announces Collaboration with FCM Global to Support Medical Cannabis R&D in Colombia

CB2 Insights (CSE:CBII, OTCQB:CBIIF) announced that it is partnering with Licensed Producer FCM Global.
November 14, 2019

CB2 Insights to Participate at Piper Jaffray’s 31st Annual Healthcare Conference

CB2 Insights today announced Prad Sekar, CEO of CB2 Insights will be participating in a panel discussion and meeting.
November 8, 2019

CB2 Insights Announces Record Revenue of $4.2 million for the Third Quarter 2019, Sequential Growth of 29 Percent

CB2 Insights (CSE:CBII; OTCQB:CBIIF) announces its results for the three and nine months ended September 30, 2019.